Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial ...
Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the ...
Penn Medicine used an artificial intelligence tool to find a treatment that aided in saving the life of a patient with ...
Hosted on MSN27d
Equillium stock rallies 26% on itolizumab study dataItolizumab demonstrated clinical efficacy after 12 weeks of treatment, with a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo. The primary endpoint of the ...
EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...
Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade in patients with rheumatoid arthritis (RA), according to ...
Botulinum toxin type A may help reduce inflammation in hidradenitis suppurativa (HS) by inhibiting mast cell degranulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback